Global Lung Cancer Therapeutics Market

Lung Cancer Therapeutics Market Size, Share, Growth Analysis, By Cancer type(Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours), By Molecule Type(Small Molecules, Biologics), By Treatment Type(Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By End Use(Hospitals, Homecare, Speciality Clinics, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2088 | Region: Global | Published Date: July, 2036
Pages: 242 | Tables: 122 | Figures: 77

Lung Cancer Therapeutics Market Dynamics

Lung Cancer Therapeutics Market Driver

  • The rise in chronic tobacco use is to blame for the rise in lung cancer cases, which now account for roughly 85% of all cancer cases worldwide. It is predicted that the number of cancer cases will increase in the near future due to cigarette smoke, which contains at least 73 known carcinogens.
  • Increased environmental pollution control measures are encouraged by the serious factor of the growth in environmental pollution. However, people who are exposed to high levels of pollution for a longer period of time are more likely to develop cancer.
  • The advancement in cancer case detection has made it simpler than ever to administer lung cancer treatments like chemotherapy and surgery, which will accelerate the growth of the market for these treatments over the course of the forecast period.
  • The industry for lung cancer therapeutics is expected to benefit from the expansion and inclusion of cancer-related treatment and care by a number of insurance providers during the expected period.

Lung Cancer Therapeutics Market Restraint

  • The need for regulatory agencies with strict criteria and testing procedures to authorise treatments for lung cancer and other cancers could limit the market's expansion.
  • According to estimates, the potential for growth would decline during the projection period due to the decreased life expectancy of patients undergoing lung cancer therapy constrained by the lack of lung organ transplants.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Lung Cancer Therapeutics Market size was valued at USD 24667.82 million in 2019 and is poised to grow from USD 27235.74 million in 2023 to USD 66407.15 million by 2031, growing at a CAGR of 10.41% in the forecast period (2024-2031).

The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market 'AstraZeneca plc', 'F. Hoffmann-La Roche AG', 'Bristol-Myers Squibb Company', 'Merck & Co., Inc.', 'Pfizer Inc.', 'Novartis International AG', 'Eli Lilly and Company', 'Boehringer Ingelheim International GmbH', 'Takeda Pharmaceutical Company Limited', 'AbbVie Inc.', 'Sanofi S.A.', 'Astellas Pharma Inc.', 'Celgene Corporation', 'Eisai Co., Ltd.', 'Johnson & Johnson', 'Bayer AG', 'AbbVie Inc.', 'GlaxoSmithKline plc', 'Amgen Inc.', 'Spectrum Pharmaceuticals, Inc.'

The rise in chronic tobacco use is to blame for the rise in lung cancer cases, which now account for roughly 85% of all cancer cases worldwide. It is predicted that the number of cancer cases will increase in the near future due to cigarette smoke, which contains at least 73 known carcinogens.

One of the key reasons fueling the expansion of the lung cancer therapeutic market in 2021 is the rising adoption and demand for targeted medicines, which are regarded as the cornerstone of precision medicine due to the rising R&D activities. According to estimates, among the several therapeutic kinds, targeted therapy has the biggest market share. Targeted therapy held a market share of 51.1% and is expected to grow over the course of the forecast period. The expansion of the targeted therapy market is also being driven by a growing emphasis on lung cancer detection and subsequent treatment based on precise targeting of the tumour or cancer source.

The lung cancer treatments and diagnostics market was dominated by North America in 2021, accounting for 39.17% of value. The large percentage of elderly people in the region, the presence of numerous international and local manufacturers, and investments made to diagnose cancer at an earlier stage are only a few of the reasons for the market's expansion. However, throughout the predicted period of 2022–2028, Asia–Pacific is expected to have faster development. The region is making significant investments in radiology treatments and chemotherapies. China and Japan are prepared to raise their spending on cutting-edge immunotherapies.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Lung Cancer Therapeutics Market

Product ID: SQMIG35J2088

$5,300
BUY NOW GET FREE SAMPLE